Breaking News

Financial Report: Hospira

May 1, 2013

Quality and product related charges contribute to losses

Hospira

1Q Revenues: $884.0 million (-9%)

1Q Loss: $76.6 million (earnings were $40.2 million 1Q12)

Comments: Specialty Injectable Pharmaceuticals sales were $651.5 million, up 11%. Medication Management revenues dropped 51% to $124.5 million. Other Pharma sales were $108.0 million, down 12%. Certain quality and product related charges primarily include third party oversight and consulting costs, extended production downtime related costs, failure to supply penalties, device product review and remediation costs to address identified issues, and costs for corrective actions including product recalls.

blog comments powered by Disqus
  • Cold Chain Packaging Trends

    Cold Chain Packaging Trends

    Kristin Brooks, Contract Pharma||February 4, 2016
    Susan Li of UPS discusses supply chain trends, challenges, and packaging innovations

  • Packaging Equipment Trends Preview

    Packaging Equipment Trends Preview

    Kristin Brooks, Contract Pharma||January 26, 2016
    Christian Treitel of Bosch Packaging Technology discusses trends and capabilities

  • Tackling Drug Serialization Challenges

    Tackling Drug Serialization Challenges

    Tim Wright, editor||January 22, 2016
    Siemens and Adents together will develop a combined hardware plus software solution for pharma industry